Endocrinología

Statins Decrease the Risk of Orbitopathy in Newly Diagnosed Patients with Graves Disease

The Journal of Clinical Endocrinology & Metabolism, Volume 106, Issue 5, May 2021, Pages 1325–1332, https://doi.org/10.1210/clinem/dgab070

Published: 09 February 2021

 

Abstract

Context/objective

The aim of this study was to examine the effect of statins and other lipid-lowering agents on the development of Graves orbitopathy (GO) in patients with newly diagnosed Graves disease (GD).

Methods

Clinical, Diagnostic, and Therapeutic Aspects of Growth Hormone Deficiency During the Transition Period: Review of the Literature

Matteo Spaziani, Chiara Tarantino, Natascia Tahani, Daniele Gianfrilli, Emilia Sbardella, Andrea M Isidori, Andrea Lenzi, Antonio F Radicioni

Frontiers in Endocrinology 2021, 12: 634288

doi: 10.3389/fendo.2021.634288